Last updated: July 29, 2025
Introduction
Israel Patent IL281736, granted in 2017, pertains to a novel pharmaceutical invention. An in-depth understanding of this patent’s scope, claims, and the broader patent landscape is essential for stakeholders—whether pharmaceutical companies, legal professionals, or investors—aiming to navigate Israel’s intellectual property framework for pharmaceuticals.
This analysis provides a comprehensive review of the patent's scope, the legal and technical nuances of its claims, and contextualizes its position within the global patent landscape addressing similar therapeutic agents.
Patent Overview and Technical Background
Israel patent IL281736 appears under the general patent classifications related to pharmaceutical compositions, which include compounds, formulations, and methods for treatment of specific diseases. The patent’s title suggests a focus on a drug or therapeutic formulation, possibly involving a novel compound or a new use of an existing compound.
While specific technical details require access to the patent document, typical features of patents in this class include:
- Novel chemical entities or derivatives
- Innovative delivery mechanisms
- New therapeutic uses or indications
- Combination therapies
Analyzing claims' scope directly from the patent document is crucial to determine the degree of innovation, breadth of protection, and potential infringement risks.
Scope of the Patent: Key Aspects
1. Patent Claims Overview
Patent claims define the legal boundaries of the invention. In IL281736, the claims likely encompass:
- Compound Claims: Chemical entities with specific structures, substitutions, or stereochemistry.
- Method Claims: Methods for preparing or administering the compound.
- Use Claims: New therapeutic applications or indications for the compound.
- Formulation Claims: Specific formulations, delivery systems, or dosage regimens.
The scope’s breadth is fundamentally dictated by whether the claims are product-based (composition/compound claims), method-based, or use-based.
2. Claim Construction and Limitations
- Independent Claims: Usually broader, defining the core invention.
- Dependent Claims: Narrower, adding specific features or limitations.
In the case of IL281736, the independent claims likely cover the core chemical compound or therapeutic use, while the dependent claims specify particular embodiments, such as formulations, dosage forms, or specific patient populations.
3. Chemical Structure and Novelty
If the patent covers a chemical compound:
- The claims may specify core scaffolds with novel substitutions.
- The scope is generally limited to compounds meeting these structural criteria.
If the claims are directed towards use or method, they could have a broader impact, covering any drug or method that leverages the claimed therapeutic effect within the specified parameters.
4. Claim Validity and Scope Limitations
The scope can be challenged on grounds such as:
- Lack of novelty if similar compounds exist.
- Obviousness given prior art.
- Insufficient disclosure.
The patent’s scope is maintained if claims are substantively distinct and inventive over prior art, which the patent prosecution process in Israel reflects.
Patent Landscape and Competitive Positioning
1. Global Patent Environment
Israel’s pharmaceutical patents often intersect with international patent landscapes, especially:
- US and European patents covering similar compounds or therapeutic indications.
- Patent families filed under the Patent Cooperation Treaty (PCT) for broader international coverage.
If IL281736 pertains to a specific molecule, an analysis of similar patents reveals key competitors or collaborators.
2. Major Players and Patent Collisions
Potential overlaps with patents owned by:
- Multinational pharmaceutical giants (e.g., Pfizer, Novartis).
- Local innovation hubs in Israel.
- Universities or biotech firms focusing on similar therapeutic areas.
Collisions or licensing opportunities depend on the patent’s claim breadth and the existence of prior art.
3. Freedom to Operate and Infringement Risk
A careful review ensures the patent's claims do not encroach upon existing patents. Given the chemical or therapeutic scope:
- Narrow claims may limit infringement risks.
- Broader use or composition claims can pose challenges and require freedom-to-operate assessments.
Legal and Commercial Implications
1. Patent Priority and Term
- The patent was granted in 2017; assuming standard validity of 20 years in Israel, rights are enforceable until approximately 2037.
- The filing date determines the novelty and inventive step assessment.
2. Enforcement and Licensing
- Patent holders can enforce IL281736 against infringers.
- They can also pursue licensing deals, especially if the patent covers novel therapeutic applications or formulations.
3. Competitive Strategies
Developers may design around the patent by:
- Creating structurally distinct compounds.
- Developing different delivery systems.
- Exploring new therapeutic indications not covered by the claims.
Conclusion: Strategic Considerations
Patent IL281736’s scope anchors in its claims’ breadth, especially concerning chemical structure and therapeutic use. Its validity depends on robust novelty and inventive step, considering prior art. For innovators, understanding the patent landscape involves assessing similar patents in Israel and internationally, evaluating infringement risks, and identifying licensing opportunities.
A comprehensive freedom-to-operate analysis and monitoring of patent activities within the same therapeutic field are essential components of strategic planning.
Key Takeaways
- Scope of IL281736 hinges on its chemical, method, and use claims; narrow claims limit infringement risks but may afford lesser protection.
- The patent landscape surrounding IL281736 involves key competitors and related therapeutic patents, both in Israel and globally.
- Aligning development strategies with patent claims ensures avoidance of infringement and supports effective licensing or litigation defenses.
- Filing and prosecuting continuation or divisional patents can extend protection and cover emerging innovations in the same therapeutic area.
- Regular patent landscape analyses are necessary to adapt to evolving prior art and maintain competitive advantage.
FAQs
Q1. How broad are the claims typically in pharmaceutical patents like IL281736?
Claims can range from narrow, structurally defined compounds to broad method or use claims. The scope depends on how the patent application articulates novelty and inventive step.
Q2. Can this patent block generic drug development?
Yes, if the claims cover a core compound or therapeutic use, they can effectively prevent generic competitors from entering the market until expiration.
Q3. Are patent claims in Israel enforceable internationally?
No, patent rights are territorial; however, similar patents may be filed internationally, creating a global patent landscape.
Q4. What strategies exist for competitors to circumvent this patent?
Develop structurally distinct compounds, explore different methods of administration, or target alternative therapeutic indications outside the patent’s claims.
Q5. How does the patent landscape influence pharmaceutical R&D investment?
Thorough patent landscape analysis guides R&D, identifying protected pathways, licensing opportunities, or patent gaps that can be exploited.
References
- Israeli Patent Office. Patent IL281736 documentation and official claims.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports and PCT filings related to the therapeutic area.
- International Patent Classification (IPC) and Cooperative Patent Classification (CPC) records for similar chemical and therapeutic patents.
- Market and patent analytic platforms such as SureChEMBL, PatSeer, and Espacenet.
Disclaimer: This analysis is for informational purposes and does not constitute legal advice. Consulting patent attorneys for detailed legal opinion and patent drafting strategies is recommended.
